By acting on both GLP-1 and GIP receptors, Tirzepatide helps control blood sugar more broadly, stimulates insulin release, reduces glucagon release, slows down foods movement through the gut, and decreases appetite and food intake
In Phase 2 research reported in The New England Journal of Medicine , participants began treatment with a low introductory dose, typically between 2 and 4 mg per week, and gradually increased to target doses ranging from 8 to 12 mg over several weeks
The primary concern relates to how muscle relaxers amplify drowsiness and impair cognitive function
But, maybe do talk to your doctor about an FDA-approved drug like tirzepatide if your weight is causing problems for you
470,478,482,483,484 GLP-1RAs in the digestive system Treatment with GLP-1RAs can alleviate insulin signaling by reducing the phosphorylation of Akt protein (Decreased Akt-P) and activating Protein Kinase C- (PKC-)